AntiEGFRnano inhibites proliferation and migration of estrogen-dependent Ishikawa cells of human endometrial cancer cell line.
- Author:
Zhenyu DIAO
;
Wuguang LU
;
Peng CAO
;
Yunlong HU
;
Xing ZHOU
;
Pingping XUE
;
Li SHEN
;
Haixiang SUN
- Publication Type:Journal Article
- From:
Acta Pharmaceutica Sinica
2012;47(10):1341-6
- CountryChina
- Language:Chinese
-
Abstract:
Nanobody is a kind of antibody from camel, which misses light chain. Nanobody has the same antigen binding specificity and affinity as mAb. Moreover, because of its small molecular weight, high stability and easy preparation, nanobody has great value of biomedical applications. In this study, we successfully prepared highly pure antiEGFR nanobody in E.coli using genetic engineering techniques. Cell proliferation assay (CCK-8 assay) and migration experiments (cell scratch test and Transwell assay) indicated that the recombinant antiEGFRnano can significantly inhibit the proliferation and migration of endometrial cancer cells. These results provide a new way of thinking and methods for EGFR-targeted therapy of endometrial cancer.
